Last reviewed · How we verify
NCT04753346
Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19
trial testing Physical Activity Level in COVID 19 in 240 participants. Status unknown.
1 January 2024
Quick facts
| Lead sponsor | Ankara University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 240 |
| Start date | 15 February 2021 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Physical Activity Level
- Anxiety and Depression Assessment
- Exercise Capacity
- Pulmonary Function Test
- Cardiopulmonary Fitness Level
- Cognitive Assessment
Conditions studied
- COVID 19 — all drugs for COVID 19 →
Sponsor
Ankara University
Who can join
18 and older, any sex, with COVID 19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 (Coronavirus disease 2019) is a new infectious disease caused by a virus named as SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2). Although it can have a devastating effect on many organs, the respiratory tract is particularly affected. In the course of the disease, a wide clinical spectrum is observed, from flu-like illness to lung failure. Some of the patients who survived the disease continue to have problems such as shortness of breath, fatigue, decrease in walking distance, decrease in participation in daily life activities. These problems suggest that the effects on respiratory and cardiac functions continue even after the disease ends. This study was designed to demonstrate the effects and extent of COVID-19 on cardiopulmonary capacity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of cardiopulmonary fitness level with normal values after COVID-19 and evaluation of factors affecting physical capacity.
Kamil Turan B, Kurtaiş Aytür Y, Genç A, Gökmen D. · · 2025 · PMID 41256788 · DOI 10.5606/tftrd.2025.15374
Verify or expand the search:
- PubMed search for NCT04753346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Physical Activity Level
Trials testing the same drug.
- NCT06349109 — Physical Activity in Children With Wolff-Parkinson-White Syndrome · completed
- NCT05133622 — Physical Fitness in Young Healthy Adults After COVID-19 Infection · NA · completed
Other recruiting trials for COVID 19
Currently open trials in the same condition.
- NCT06871293 — Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19 · NA · recruiting
- NCT06599658 — COVID-19 Booster and IIV Schedule in Immunocompromised Hosts · Phase 2 · recruiting
- NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
- NCT04522076 — Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acq · active not recruiting
- NCT06702540 — Bio-reconfigurable Electronic Platform for Multiplex Detection of Viral Respiratory Pathogens · active not recruiting
Other Ankara University trials
Trials by the same sponsor.
- NCT07441837 — Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients · Phase 2 · not yet recruiting
- NCT07536490 — Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease · not yet recruiting
- NCT06959433 — Lu-177 PSMA Treatment in Cell Renal Carcinoma · Phase 3 · not yet recruiting
- NCT07513272 — EFFECT OF BALLS ON PAIN AND ANXIETY DURING VENIPUNCTURE IN CHILDREN · NA · not yet recruiting
- NCT07536542 — Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04753346 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara University
- Last refreshed: 15 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04753346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing